DIFFERENCES OF LIVER FUNCTION TESTS IN TYPE 2 DIABETES MELLITUS PATIENTS WITH AND WITHOUT CORONARY ARTERY DISEASE
DOI:
https://doi.org/10.24293/ijcpml.v24i3.1408Keywords:
Type 2 diabetes mellitus, coronary arterial disease, liver functionAbstract
One of the macroangiopathic complications of Diabetes Mellitus (DM) is Coronary Arterial Disease (CAD). Several studies showed that the liver was one of the organs involved in the pathological development of diabetes.The aim of this study was to find the differences of liver function in type 2 DM patients with CAD and without CAD. This was an analytical observational study with cross-sectional design. Forty-four type 2 DM patients with and without CAD at the Adam Malik Hospital Medan who came during June - August 2016 were studied for liver function (total bilirubin, direct bilirubin, AST and ALT). In this study, the average values of total bilirubin and direct bilirubin level in patients with CAD were found to be lower than without CAD. Statistically a significant difference revealed a total bilirubin (p < 0.001) and direct bilirubin (p = 0.001) in type 2 DM patients with and without CAD. There was a significant difference in liver function tests in DM type 2 patients with, and without coronary arterial disease, these data suggested that total billirubin and direct billirubin levels in type 2 DM patients with CAD were found lower than those without CAD.
Downloads
References
Gavin JR, Alberti KGMM, Davidson MB, DeFronzo RA, Drash A, Gabbe SG. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2001; 24(1): S5-S20.
Kemenkes RI. Situasi dan analisis diabetes. Jakarta, Pusat Data dan Informasi Kemenkes RI. 2014; 1-8.
Kemenkes RI. Profil kesehatan Indonesia tahun 2013. Jakarta, Badan Penelitian dan Pengembangan Kemenkes RI. 2013; 116.
Diabetes Drafting Group Prevalence of small vessel and large vessel diseases in diabetics patients from 14 centers. Diabetologia 1985; 28: 615–640
Ni Han, Soew HHK, Htet A. Determinants of abnormal liver function tests in diabetes patients in Myanmar. International Journal of Diabetes Research 2012; 1(3): 36–41.DOI: 10.5923/j.diabetes.20120103.02
Idris AS, Mekky KFH, Abdalla BEE, Ali KA. Liver function test in type 2 sudanese diabetic patients. International Journal of Nutrition and Metabolism 2011; 3(2):17-21.
Marzuki Suryaatmadja. Glycated Albumin: Untuk pemantauan diabetes melitus yang lebih baik. Summit Diagnostic Update. 2014; 11: Q4.
Harris EH. Elevated liver function tests in type 2 diabetes. Clinical Diabetes 2005; 23(3): 115-119.
Levinthal GN, Tavill AS. Liver disease and diabetes mellitus. Clinical Diabetes 1999; 17(2): 1-20.
Jayarama N, Sudha R. A Study of non-alcoholic fatty liver disease (nafld) in type 2 diabetes mellitus in a tertiary care centre, Southern India. Journal of Clinical and Diagnostic Research. 2012; 6(2): 243–245.
Vitek L. The role of bilirubin in diabetes, metabolic syndrome and cardiovascular disease. Edited by Kapitulnik J. Frontiers in pharmacology. 2012; 3(55): 1-5.
Lin JP, Vitek L. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clinical Chemistry, 2010; 56(10):1535-1541.
Ramesh R, NA Kumaran, VK Velu, Reeta R, Sathish M, Niranjan G. Association between hepato-biliary status and HbA1c in type 2 diabetes mellitus with Coronary Artery Disease (CAD). http://www.scirp.org/journal/jdm. 2015.
Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM and Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arteriosclerosis, thrombosis and vascular biology, 1996; 16: 250 – 255. http://dx.doi.org/10.1161/01.ATV.16.2.250
